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Introduction: Type 2 diabetes mellitus and chronic kidney disease (CKD) are conditions which
have a high prevalence in individuals ≥65 years of age and represent a major public health
problem.
Objectives:  To determine the prevalence of CKD, its categories and its relationship with var-
ious  demographic and clinical factors in elderly patients with type 2 diabetes mellitus in
Spain.
Methods:  Observational, cross-sectional, multicenter, Spanish epidemiological study.
Patients  with known type 2 diabetes mellitus, age ≥65 years of age treated in Primary Care
were  included. We  collected demographic, anthropometric and analytical variables from the
previous 12 months, including the albumin-to-creatinine ratio and estimated glomerular
filtration  rate to evaluate renal function.
Results: The prevalence of CKD was 37.2% (95% CI, 34.1–40.3%), renal failure was  29.7%
(95%  CI, 26.8–32.6%) and increased albuminuria was 20.6% (95% CI, 17.3–23.9%), mod-erately  increased albuminuria was 17.8% (95% CI, 14.7–20.9%) and severely increased
albuminuria  was 2.8% (95% CI, 1.4–4.2%). In turn, the prevalence of CKD categories were:
G1  1.3% (95% CI, 0.6–2%), G2 6.2% (95% CI, 4.6–7.8%), G3a 17.2% (95% CI, 14.8–19.6%),
G3b  9.8% (95% CI, 7.9–11.7%), G4 2% (95% CI, 1.1–2.9%) and G5 0.7% (95% CI, 0.2–1.2%).
DOI of original article:
ttps://doi.org/10.1016/j.nefro.2017.11.025.
 Please cite this article as: Martínez Candela J, Sangrós González J, García Soidán FJ, Millaruelo Trillo JM, Díez Espino J, Bordonaba Bosque
, et al. Enfermedad renal crónica en Espan˜a:  prevalencia y factores relacionados en personas con diabetes mellitus mayores de 64 an˜os.
efrologia.  2018;38:395–407.
∗ Corresponding author.
E-mail  address: juanmartinezcandela@gmail.com (J. Martínez Candela).
013-2514/© 2018 Sociedad Espan˜ola  de Nefrologı´a. Published by Elsevier Espan˜a,  S.L.U. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
396  n e f r o l o g i a. 2 0 1 8;3 8(4):395–407
In the multivariate analysis, after adjusting for the remaining variables, CKD was  associated
with elderly age (OR 5.13, 95% CI, 3.15–8.35), high comorbidity (OR 3.36, 95% CI, 2.2–5.12) and
presence of antihypertensive treatment (OR 2.43, 95% CI, 1.48–4.02).
Conclusions:  CKD is frequent in the diabetic population ≥65 years of age and is associated
with elderly age, high comorbidity and with treated hypertension. No relationship has been
found with gender and time in years since onset of diabetes.
©  2018 Sociedad Espan˜ola  de Nefrologı´a. Published by Elsevier Espan˜a,  S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Enfermedad  renal  crónica  en  Espan˜a:  prevalencia  y  factores  relacionados
en  personas  con  diabetes  mellitus  mayores  de  64  an˜os
Palabras clave:
Enfermedad renal crónica
Categorías,  ancianos
Dependencia
Comorbilidad
Diabetes  mellitus tipo 2
r  e  s  u  m  e  n
Introducción: La diabetes mellitus tipo 2 y la enfermedad renal crónica (ERC) son afecciones
de elevada prevalencia en personas ≥ 65 an˜os  y constituyen un importante problema de
salud pública.
Objetivos: Conocer la prevalencia de la ERC, sus categorías y su relación con diversos factores
demográficos y clínicos, en pacientes ancianos con diabetes mellitus tipo 2 en Espan˜a.
Métodos:  Estudio epidemiológico, observacional, transversal, multicéntrico, ámbito nacional.
Se incluyeron pacientes con diabetes mellitus tipo 2 conocida, edad ≥ 65 an˜os  atendidos en
Atención Primaria. Se recogieron variables demográficas, antropométricas y analíticas de
los últimos 12 meses, incluyendo el cociente albúmina-creatinina y el filtrado glomerular
estimado para evaluar la función renal.
Resultados: La prevalencia de ERC fue del 37,2% (IC95%, 34,1-40,3%), de insuficiencia renal
del 29,7% (IC95%, 26,8-32,6%) y de elevación de la albuminuria del 20,6% (IC95%, 17,3-23,9%),
moderadamente elevada 17,8% (IC95%, 14,7-20,9%), severamente elevada 2,8% (IC95%, 1,4-
4,2%). La prevalencia de las categorías de ERC fueron: G1 1,3% (IC95%, 0,6-2%), G2 6,2% (IC95%,
4,6-7,8%), G3a 17,2% (IC95%, 14,8-19,6%), G3b 9,8% (IC95%, 7,9-11,7%), G4 2% (IC95%, 1,1-2,9%)
y G5 0,7% (IC95%, 0,2-1,2%).
En  el análisis multivariante, después de ajustar por el resto de variables, la ERC se asoció
a mayor  edad OR 5,13, (IC95%, 3,15-8,35), alta comorbilidad OR 3,36 (IC95%, 2,2-5,12) y la
presencia de tratamiento antihipertensivo OR 2,43 (IC95%, 1,48-4,02).
Conclusiones:  La ERC es frecuente en la población diabética ≥ 65 an˜os  y se asocia con mayor
edad, alta comorbilidad e hipertensión tratada. No se ha encontrado asociación con el género
y an˜os  de evolución de la diabetes.
© 2018 Sociedad Espan˜ola  de Nefrologı´a. Publicado por Elsevier Espan˜a,  S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
Chronic kidney disease (CKD) is a common comorbidity in
patients  with type 2 diabetes mellitus (DM2) and in both con-
ditions  the prevalence is increasing.
Worldwide epidemiological data show that DM2  is one of
the  main epidemics of the 21st century. Approximately 415
million  people (between 20 and 79 years old) suffered from
this  condition in 2015, of which 94.2 million (22.7% of the total)
were  between 65 and 79 years old. In addition, 318 million
people  were  at a high risk of developing DM2. It is estimated
to  that DM2  will affect 642 millions in the 2040s (one out of ten
adults  will have the disease) and almost a third of them will
be  between 65 and 79 years. Sources from the International
Diabetes Federation1 indicates that DM2  is more  common in
men than in women.by-nc-nd/4.0/).
According  to the Di@bet.es study,2 the prevalence of DM2  in
Spain  increases with age and is higher in men  than in women
except  in those older than 75 years, with a prevalence of 40%
(41.3%  in women  and 37.4% in men) while in the 61–75 years
group,  between, the prevalence is 42.4% in men and 29.8% in
women.  The data on DM in our country in people over 60 years,
which  is between 18 and 25%, are similar to the United States
population  of 65 or older, which was 25.9% in 2012, affecting
11.2  million people.3
Chronic kidney disease (CKD) is associated with an increase
in  cardiovascular morbidity and mortality, mortality from any
cause and progression of kidney disease, both in the general
population and in patients with DM2.4 The prevalence of CKD
in  adult populations in Western countries varies from 5.8%
in  Poland to 14.8% in the United States.5,6 The prevalence of
CKD  increases with age and in people with diabetes, in which
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he prevalence of CKD varies between 34.7 and 45.4% accord-
ng  to populations.6–10 In our country, according to data from
he  Epirce study,11 CKD affects 9.16% of the adult population
ver 20 years of age (23.7% in people over 65 years of age) and
he  prevalence of CKD in people with diabetes reaches 27.9%
ccording  to the Percedime2 study,12 with an average age of
6.8  years.
The present work is part of the ESCADIANE study (Study of
he  characteristics of elderly patients with diabetes in Spain)
esigned  by the Group of Primary Care of the Spanish Society
f  Diabetes. The main objective is to evaluate the prevalence
f  CKD and its different stages in patients with diabetes aged
65  years in Spain and determine their relationship with var-
ous  demographic factors (gender, age) and clinical features:
lycemic  control, years of evolution of their DM, anthropo-
etric measures, current treatments, hypoglycemic episodes,
egrees  of dependence and comorbidity.
ethods
tudy  design
he present work is part of the ESCADIANE study, an epidemi-
logical,  observational, cross-sectional, multicenter, national
tudy,  that aims to know the health status of diabetics patients
lder  that 65 years in Spain.
The  study population includes patients being followed by
hysicians  researchers, with the diagnosis of DM2 (following
he  criteria of the American Diabetes Association 2011)13 being
ecorded  in the clinical history, with an age ≥65 years and
ith  the necessary data to complete the questionnaire. The
articipants  in the study had to sign the informed consent
the  participant or his legal representative) and they were  not
ncluded  in any other type of epidemiological study. Patients in
 terminal situation and those who did not meet the inclusion
riteria  were  excluded, according to the evaluation commit-
ee.  The study was  qualified as an observational-type EPA-OD
tudy  by the Spanish Agency of Medications and it was  evalu-
ted  and approved by the CEIC of Aragón on January 30, 2013.
rocedure
ealth professionals of Primary Health Care from the different
utonomous regions participated as researchers. The distribu-
ion  of participants was  proportional to the population of each
f  the regions of Spain.
Each  medical researcher was  asked to select twelve of his
atients  with DM of 65 years or older. A sequence of random
umbers was  provided through which the 12 patients in a list
hould  be selected.
The  data collection was  developed between October 2014
nd  April 2015, in the context of usual clinical practice.
Finally, 82 primary care physicians of the ESCADIANE study,
hroughout the Spanish geography, included 939 patients that
ere  used for the analysis of kidney disease.(4):395–407  397
Measurements
The following demographic and anthropometric variables
were  collected: age, gender, weight (kg), height (cm), body
mass  index (BMI) (kg/m2), abdominal perimeter (cm) and waist
circumference/height ratio (R W/H).
Also recorded was, the presence of cardiovascular risk
factors  (arterial hypertension [HTN] and dyslipidemia), car-
diovascular  diseases and other events with a confirmed
diagnosis and dated in the clinical history: cerebrovascular
disease and sequelae (hemiplegia or paraplegia), coronary
heart  disease (myocardial infarction, angina pectoris, coro-
nary  interventions), heart failure, symptomatic peripheral
arteriopathy, retinopathy, neuropathy, chronic respiratory dis-
ease, rheumatic diseases, mild or severe liver disease, peptic
ulcer,  neoplasms (lymphomas, leukemias, solid tumors and
presence  of metastasis), advanced CKD or dialysis and chronic
cognitive  impairment.
Clinical  and analytical variables were also collected: years
of  evolution of DM2, hypoglycemia recorded in the clinical
history  requiring medical assistance, blood pressure (mmHg),
smoking  habits (smoker, ex-smoker, non-smoker), alcohol
consumption (drinker, ex-drinker, no drinker), medications
taken by the patient at the time of data collection (antidia-
betic,  antihypertensive, lipid-lowering, antiplatelet agents and
anticoagulants),  Barthel index, basal glycemia (mg/dl), gly-
cosylated  hemoglobin (HbA1c,%), lipid profile (mg/dl), serum
creatinine  (mg/dl) and the albumin/creatinine ratio (ACR)
(mg/g)  in morning urine sample. Blood biochemistry was  per-
formed  in the reference laboratory of each researcher.
Obesity was  defined as BMI  ≥ 30 kg/m2. Abdominal obesity,
as  waist circumference >102 cm (men) or >88 cm (women).
Hypertension was  defined as blood pressure ≥140/90 mmHg
or  the use of antihypertensive medications. Hyperlipidemia
was considered if total cholesterol was >200 mg/dl or LDL-C
cholesterol >100 mg/dl or HDL cholesterol <40 mg/dl in men
and  <50 mmol/kg in women or triglycerides >150 mg/dL or
lipid-lowering drug therapy, according to the American Dia-
betes  Association 2011.13
The level of dependence was evaluated by the Barthel
Index14; patients were  classified according to the score in:
independent (100 points), mild dependence (91–99 points),
moderate dependence (61–90 points), severe or serious
dependence (21–60 points) and total dependence (0–20 points).
Comorbidity was  assessed using original Charlson Index.15
Patients were classified according to the score of comorbidity
in  absence: 0–1 points, low: 2 points and high: ≥3 points.
The  kidney function was  defined according to the crite-
ria  of the Kidney Disease: Improving Global Outcomes KDIGO
201216 and the Spanish Consensus Document for the detection
and  management of CKD17; the presence of CKD was  consid-
ered  in patients with an estimated renal glomerular filtration
rate  (eGFR) <60 mL/min/1.73 m2 and/or the presence of kidney
damage  (defined as a Albumin/Cr (ACR) in urine greater than
or  equal to 30 mg/g); the glomerular filtration rate (GFR) was
estimated  using the Chronic Kidney Disease-Epidemiology
18Collaboration equation. Renal insufficiency (RI) was consid-
ered  if the eGFR <60 mL/m/1.73 m2. Albuminuria was  defined
as  a ACR of 30 mg/g or more,  regardless of gender. The cat-
egories  of albuminuria were: normal A1 or mild increase
 0 1 8;3 8(4):395–407
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Fig. 1 – Prevalence of CKD, classified into categories
following the KDIGO guidelines. CKD categories. G1:
eGFR  ≥ 90 mL/m/1.73 m2 and ACR ≥ 30 mg/g; G2: eGFR
60–89 mL/m/1.73 m2 and ACR ≥ 30 mg/g; G3A: eGFR
45–59  mL/m/1.73 m2; G3B: eGFR 30–44 mL/m/1.73 m2; G4
eGFR 15–29 mL/m/1.73 m2; G5 eGFR < 15 mL/m/1.73 m2;
eGFR:  estimated glomerular filtration; ACR:398  n e f r o l o g i a. 2
(ACR < 30 mg/g), A2 moderate increase (ACR 30–299 mg/g) and
A3  severe increase (ACR ≥ 300 mg/g). The categories of CKD
were  defined as follows: G1 (eGFR ≥ 90 ilamL/min/1.73 m2
and ACR ≥ 30 mg/g); G2 (eGFR 60–89 mL/min/1.73 m2 and
ACR  ≥ 30 mg/g); G3a (FGe 45–59 mL/min/1.73 m2 regardless of
ACR);  G3b (FGe 30–44 mL/min/1.73 m2 regardless of ACR); G4
(FGe  15–29 mL/min/1.73 m2 independently of the ACR) and
G5  (FGe < L15 mL/min/1.73m2 independently of the ACR). The
eGFR  categories (G1 to G5) are defined with the same eGFR
intervals  independently of the ACR. The final analysis of the
study  was  performed using a single determination of creat-
inine  and albuminuria, as no further values were available.
The  variable race was  not taken into account, given the char-
acteristics  of the population of our environment, where the
Caucasian  race (99%) is clearly predominant, especially in this
age group.
Statistic  analysis
A descriptive analysis of the demographic, anthropometric,
analytical and comorbidities variables was  performed. Val-
ues  of continuous variables have been described by central,
non-central tendency and dispersion. Qualitative variables by
absolute and relative frequency distributions with 95% CI.
For  comparison of quantitative variables and qualitative vari-
ables,  it was  proved, by the Kolmogorov–Smirnov test, whether
quantitative variables followed a normal distribution in the
categories  of qualitative variables. Parametric tests (t-Student
test  or ANOVA) were  used in the case of normality, otherwise
nonparametric tests (Mann Whitney U or Kruskal Wallis test)
were  used, all of them as independent samples.
The Chi-square test was  used to compare proportions and
the  Yates correction was  used as necessary. In case of mul-
tiple  comparisons, p-values were  corrected by the Bonferroni
method. The degree of association between the demographic
and  clinical characteristics of the patients and the presence or
absence of CKD was  established by multivariate logistic regres-
sion.  Statistical significance was  established at 0.05 when
hypotheses were tested. The analysis and processing of the
data  was  done using the IBM SPSS Statistics Software v.23.
Results
The study included 939 patients from a total of 82 primary care
physicians  distributed throughout the Spanish geography; 929
provided the creatinine value and were included in the analy-
sis  of kidney disease. Of these, 608 (65.5%) had a determination
of  the ACR. The average age of the participants was  76.4 years
(standard  deviation [SD] 6.7), 52.9% (95% CI: 49.7–56.1) were
women.  The demographic, anthropometric and clinical char-
acteristics  of the participants are shown in Table 1.
Compared with men, women had a higher mean age,
BMI,  waist circumference/height ratio, worse lipid profile, and
higher  degree of dependency. By contrast, men  had higher cre-
atinine levels, more  comorbidity and worse habits in terms of
tobacco  and alcohol. No differences were  found in terms of
years  of evolution of DM2, glycemia, HbA1c, blood pressure,
glomerular filtration rate and ACR in urine.albumin/creatinine ratio.
Prevalence  and  characteristics  of  chronic  kidney  disease
The prevalence of CKD was  37.2% (95% CI, 34.1–40.3%), that
of  RI was  29.7% (95% CI, 26.8–32.6%) and high albuminuria
was  present in 20.6% (95% CI, 17.3–23.9%): moderately elevated
17.8%  (95% CI, 14.7–20.9%) and severely elevated 2. 8% (95%
CI,  1.4–4.2%). The prevalence of CKD according to categories
following the KDIGO guidelines and the Spanish consensus
document for the detection and management of CKD17 is
shown  in Fig. 1. Table 2 describes the characteristics of patients
according  to the presence of CKD.
Bivariate statistics comparing patients with CKD and with-
out  CKD, no statistically significant differences were  found
in  gender, peripheral obesity, abdominal obesity, waist cir-
cumference/height, glycemic control and the presence of
microvascular diseases. However, patients with CKD had a
longer duration of diabetes, more  age (higher proportion of
CKD  in older age groups), presence of macrovascular disease,
more  hypoglycaemia, greater insulin utilization and less use
of  oral antidiabetic drugs, than those without CKD. The preva-
lence  of kidney disease increased according to the degree of
dependence  (35.8% independence-mild dependence vs. 56.3%
moderate-severe dependence p < 0.0001) and also according to
degree of comorbidity, 24.7%. 54.2%, p < 0.001, according to the
absence  of morbidity or high morbidity respectively.
The prevalence of CKD considering only the patients
that provide albuminuria determination was  39.5% (95% CI
35.6–43.4%).
The  prevalences of the different categories of eGFR (G1,
G2,  G3A, G3B, G4–G5) were:  13.9% (95% CI, 11.7–16.1%), 56.4%
(95%  CI, 53.2–59.6%), 17.2% (95% CI, 14.8–19.6%), 9.8% (95% CI,
7.9–11.7%)  and 2.7% (95% CI, 1.7–3.7%) respectively.
The deterioration of renal function was  associated with a
longer  duration of diabetes, older age, worse glycemic control,
presence  of micro- or macrovascular disease, greater number
of  hypoglycaemia episodes, greater degree of dependence and
n e f r o l o g i a. 2 0 1 8;3  8(4):395–407  399
Table 1 – Characteristics of patients with DM2  over 65 years (n = 939).
Total Men Women p-Value*
N (%) 939 442 (47.1%) 497 (52.9%)
Mean (SD)
Age  (years) 76.4 (6.7) 75.8 (6.3) 77 (7) 0.006
Years evolution 11.6  (7.9) 11.4 (7.3) 11.9 (8.4) 0.337 (ns)
BMI (kg/m2) 29.5 (4.6) 29.1 (4) 29.8 (5.1) 0.019
Waist circumference (cm) 101.2 (12.2) 104 (11) 98.7 (12.6) 0.000
RW/H 0.63 (0.08) 0.62 (0.07) 0.64 (0.09) 0.002
Barthel Index 92.43 (17.6) 94.9 (15.5) 90.2 (18.9) 0.000
Charlson Index 2.7 (1.9) 2.9 (2) 2.5 (1.8) 0.001
Glycemia (mg/dl) 137 (39.6) 138.7 (38.8) 135.6 (40.3) 0.236 (ns)
HbA1c (%) 7.04 (1.16) 7.03 (1.13) 7.05 (1.19) 0.732 (ns)
SBP (mmHg) 135.9 (15.4) 136.1 (14.8) 135.7 (15.9) 0.731 (ns)
DBP (mmHg) 74.7 (9.9) 75.2 (9.7) 74.3 (10.1) 0.205 (ns)
Total cholesterol (mg/dl) 173.8 (37.2) 164.3 (34.6) 182.1 (37.5) 0.000
HDL-cholesterol (mg/dl) 50.9 (14.8) 47.1 (13.9) 54.2 (14.8) 0.000
LDL-cholesterol (mg/dl) 95.6 (32.2) 91 (30.7) 99.7 (33.1) 0.000
Triglycerides (mg/dl) 139 (70.3) 132.6 (71.3) 144.8 (68.9) 0.008
Creatinine (mg/dl) 0.97 (0.47) 1.09 (0.51) 0.87 (0.40) 0.000
eGFR (mL/m/1.73 m2) 70.4 (19.4) 71.3 (19.0) 69.6 (19.7) 0.187 (ns)
ACR (N = 608) (mg/g) 39.9 (103.8) 48.1 (113.3) 32.2 (93.5) 0.060 (ns)
Smoking habits (%)
Smoker  62 (6.7%) 49 (79%) 13 (21%) 0.001
Former smoker 214 (23%) 195 (91.1%) 19 (8.9%)
Non smoker 656 (70.3%) 195 (29.7%) 461 (70.3%)
Use of alcohol (%)
Drinker  212 (22.7%) 178 (84%) 34 (16%) 0.001
Ex-drinker 67 (7.1%) 63 (94%) 4 (6%)
Non-drinker 654 (70.2%) 199 (30.4%) 455 (69.6%)
ACR: albumin creatinine ratio in urine; SD: standard deviation; HbA1c: glycosylated hemoglobin; BMI: body mass index; ns: not significant; SBP,
DBP: systolic, diastolic blood pressure; R W/H: waist height ratio.
∗ For qualitative variables (n [%]): p-value chi-squared test (Bonferroni correction for multiple comparisons). For quantitative variables: para-
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reater presence of comorbidity. No statistically significant
ifferences were  found regarding CKD, between the different
nthropometric measurements and gender.
Regarding treatment, 25.2% of patients were on insulin,
he  use of insulin was  significantly increased in patients
ith  deterioration of renal function. Regarding oral antidia-
etics  (OAD), 70.2% used metformin, 28.7% inhibitors of the
nzyme  dipeptidyl peptidase-4 (IDPP-4) and 16.3% sulfony-
ureas  (SU) (glibenclamide 1.2%, 36.4% of them in categories
–5  of ER) alone or in combination. The use of metformin
nd SU decreases as renal function worsens; in patients with
GFR  <60 mL/m/1.73 m2, 24.3% use metformin and 26.4% sul-
onylureas  and in those with eGFR < 30 mL/m/1.73 m2  only
.8%  (95% CI, 0.1–1.5%) and 2.6% (95% CI 0.1–5.1%) use met-
ormin  and SU respectively. Likewise, 1.7% (95% CI, 0.3–3.1%)
f  the patients used thiazide diuretics for the treatment of
heir  HTN with eGFR < 30 mL/m/1.73 m2. In these situations,
he  use of drugs (metformin, sulfonylureas) would be formally
ontraindicated for safety reasons or not recommended due
o  lack of efficacy as in the case of thiazides. Almost 70% of
atients  include an inhibitor of the renin–angiotensin sys-
em  in their treatment regimen for hypertension and 65% use
tatins  (Table 3).
Finally,  in the multivariate analysis, renal disease was asso-
iated  with older age OR: 5.13 (95% CI, 3.15–8.35 p < 0.001), highution, and otherwise nonparametric test (U-Mann Whitney, Kruskal
comorbidity OR: 3.36 (95% CI, 2.20–5.12 p < 0.001) and anti-
hypertensive treatment OR: 2.43 (CI 95%, 1.48–4.02, p < 0.001)
(Table  4).
Discussion
The objective of the treatment of diabetes in the elderly is to
maintain  their functional capacity and quality of life, and pre-
vent  complications. However, this type of patients not only
have  to face their disease, but also additional burdens related
to  the process of aging, associated comorbidities and a higher
percentage  of geriatric syndromes. It has been evidenced
that  elderly patients with diabetes have a high prevalence of
disability  and functional deterioration, which produces a sig-
nificant impact on the treatment and management of their
diabetes.19,20
DM2 and chronic kidney disease are chronic conditions that
often  coexist in people older than 65 years, in which hypo-
glycaemic episodes and pharmacological adverse events, that
may  worsen their quality of life, must be avoided.Decision making in this group of patients is complex;
aspects other than biomedical objectives must be addressed,
including morbidity and life expectancy. In this regard, it is
remarkable  the low level of HbA1c achieved in the patients
400  n e f r o l o g i a. 2 0 1 8;3 8(4):395–407
Table 2 – Characteristics of patients with and without kidney disease (n = 929).
Total Kidney disease No kidney disease p-Value*
N (%) 929 346 (37.2%) 583 (62.8%)
Years of evolution (mean, SD) 11.6 (7.9) 12.8 (8.5) 10.9 (7.4) <0.001U Mann–Whitney
Gender, N (%)
Males  437 (47) 159 (36.4) 278 (63.6) ns
Females 492 (53) 187 (38) 305 (62)
Age groups N (%)
65–74  a 390 (42.0) 95 (24.4) a 295 (75.6) a <0.001
75–84 a 404 (43.5) 168 (41.6) b 236 (58.4) b
≥85 135 (14.5) 83 (61.5) c 52 (38.5) c
BMI (kg/m2), N (%)
≤30 560 (60.3) 202 (36.1) 358 (63.9) ns
>30 368 (39.7) 144 (39.1) 224 (60.9)
Central obesity, n (%)
Yes  626 (68.3) 238 (38) 388 (62) ns
No 290 (31.7) 101 (34.8) 189 (65.2)
R W/H, N (%)
≤0.55  122 (13.3) 40 (32.8) 82 (67.2) ns
>0.55 794 (86.7) 299 (37.7) 495 (62.3)
HbA1c, N (%)
<7%  534 (57.7) 188 (35.2) 346 (64.8) ns
7–8.5% 289 (31.2) 108 (37.4) 181 (62.6)
>8.5% 103 (11.1) 48 (46.6) 55 (53.4)
Macrovascular disease, N (%)
Yes  266 (28.8) 123 (46.2) 143 (53.8) <0.001
No 658 (71.2) 222 (33.7) 436 (66.3)
Microvascular disease, N (%)
Yes  160 (17.3) 70 (43.8) 90 (56.2) ns
No 763 (82.7) 275 (36) 488 (64)
Hypoglycemia, N (%)
Yes  116 (12.5) 57 (49.1) 59 (50.9) <0.005
No 812 (87.5) 289 (35.6) 523 (64.4)
Insulin
Yes 234 (25.2) 112 (47.9) 122 (52.1) <0.001
No 693 (74.8) 234 (33.8) 459 (66.2)
OAD
Yes 763 (82.3) 268 (35.1) 495 (64.9) <0.003
No 164 (17.7) 78 (47.6) 86 (52.4)
OAD: oral antidiabetics; SD: standard deviation; KD: kidney disease; HbA1c: glycosylated hemoglobin; BMI: body mass index; ns: not significant;
R W/H: waist height ratio.
In  variables with more than two categories, the letters a, b or c that differ indicate in which categories the differences are statistically significant.
i corrComparison by rows.
∗ For qualitative variables (n [%]): p-value chi-squared test (Bonferron
from our study, 7.04% of patients, with a mean age of 76.4
years,  and a 88.9% of patients with values lower than 8,5%,
values  that are similar to those obtained in other studies
conducted in our environment,4,12,21–23 with HbA1c between
6.84 and 7.3%, mean ages between 66.7 and 68.8 years and a
80–88%  of patients with HbA1c < 8.5%. In studies from other
Western  countries (United States, Finland and France)8,9,24 in
patients  with average ages between 60.5 and 71.2 years, the
mean  HbA1c values were between 7.03 and 7.2%, Similar the
values  observed in our study, which may  suggest a possible
overtreatment of this type of patients, which together with the
deterioration  of their renal function may  favor hypoglycemic
episodes.ection in multiple tests).
In  the studied population, attended by PC physicians and
with  an average of 11.6 years evolution of their DM,  the preva-
lence  of CKD was 37.2%, of RI (eGFR < 60 mL/m/1.73 m2) was
29.7%  and with albuminuria 20.6% (moderately high 17.8%,
severely  high 2.8%). These results show a prevalence of CKD
which  is higher than in recent studies in our country. In
the  Percedime study212 performed by PC in outpatients clin-
ics  in a diabetic population >40 years of age, mean age of
66.8  years and an average of 9 years of evolution of their
DM2,  the reported prevalence of CKD was 27.9%, 18% had
RI  and albuminuria was  present in 15.4% (moderately high
13%,  severely increased 3.2%); unlike our study and others
performed in Spain and in other countries, several analytical
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Table 3 – Characteristics of patients according to categories of chronic kidney disease (n = 929).
mL/m/1.73 m2 G1 KD eGFR ≥ 90 G1 no KD eGFR ≥ 90 G2 KD eGFR 60–89 G2 no KD eGFR 60–89 G3A eGFR 45–59 G3B eGFR 30–44 G4-5 eGFR <30 p-Value*
N = 929, KD = 346 (37.2%) 12 (1.3) 117 (12.6) 58 (6.2) 466 (50.2) 160 (17.2) 91 (9.8) 25 (2.7)
Years evolution, M(SD) 11.7 (8.1) 11.3 (8.4) 10.9 (8.3) 10.9 (7.1) 12.8 (7.6) 13.9 (9.9) 13.6 (9.0) 0.008
HbA1c (%), M(SD) 7.5 (1.4) 7.2 (1.2) 7 (1.4) 6.9 (1.0) 7.07 (1.2) 7.19 (1.3) 7.40 (1.2) ns
Age group, n (%)
65–74  years 8 (2.1) 96 (24.6) a 20 (5.1) 199 (51) 43 (11) a 17 (4.4) a 7 (1.8) <0.001
75–84 years 4 (1) 19 (4.7) b 33 (8.2) 217 (53.7) a 75 (18.6) 44 (10.9) 12 (3)
≥85 years 0 (0) 2 (1.5) b 5 (3.7) 50 (37) b 42 (31.1) b 30 (22.2) b 6 (4.4)
Gender, n (%)
Male  5 (1.1) 50 (11.4) 35 (8) 228 (52.2) 73 (16.7) 32 (7.3) 14 (3.2) ns
Female 7 (1.4) 67 (13.6) 23 (4.7) 238 (48.4) 87 (17.7) 59 (12) 11 (2.2)
R W/H, n (%)
≤0.55  1 (0.8) 20 (16.4) 6 (4.9) 62 (50.8) 18 (14.8) 8 (6.6) 7 (5.7) ns
>0.55 11 (1.4) 96 (12.1) 51 (6.4) 399 (50.3) 138 (17.4) 81 (10.2) 18 (2.3)
BMI (kg/m2), n (%)
BMI ≤ 30 6 (1.1) 71 (12.7) 33 (5.9) 287 (51.2) 97 (17.3) 51 (9.1) 15 (2.7) ns
BMI > 30 6 (1.6) 46 (12.5) 25 (6.8) 178 (48.4) 63 (17.1) 40 (10.9) 10 (2.7)
Central obesity, n (%)
Yes  9 (1.4) 81 (12.9) 42 (6.7) 307 (49) 104 (16.6) 67 (10.7) 16 (2.6) ns
No 3 (1) 35 (12.1) 15 (5.2) 154 (53.1) 52 (17.9) 22 (7.6) 9 (3.1)
HbA1c groups, n (%)
<7%  7 (1.3) 63 (11.8) 37 (18.1) 283 (53) 91 (17) 45 (8.4) 8 (1.5) a 0.023
7–8.5% 1 (0.3) a 37 (12.8) 14 (4.8) 144 (49.8) 50 (17.3) 30 (10.4) 13 (4.5) b
>8.5% 4 (1.3) b 17 (16.5) 7 (6.8) 38 (36.9) 19 (17.8) 15 (14.6) 3 (2.9)
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– Table 3 (Continued)
mL/m/1.73 m2 G1 KD eGFR ≥ 90 G1 no KD eGFR ≥ 90 G2 KD eGFR 60–89 G2 no KD eGFR 60–89 G3A eGFR 45–59 G3B eGFR 30–44 G4-5 eGFR <30 p-Value*
Hipoglycemia, n (%)
Yes 0  (0) 12 (10.3) 7 (6.0) 47 (40.5) a 24 (20.7)) 18 (15.5) a 8 (6.9) a 0.005
No 12 (1.5) 105 (12.9) 51 (6.3) 418 (51.5) b 136 (16.7) 73 (9.0) b 17 (2.1) b
Macrovascular disease, n (%)
Yes  3 (1.1) 27 (10.2) 20 (7.5) 116 (43.6) a 52 (19.5) 34 (12.8) 14 (5.3) a 0.004
No 9 (1.4) 90 (13.7) 38 (5.8) 346 (52.6) b 107 (16.3) 57 (8.7) 11 (1.7) b
Microvascular disease, n (%)
Yes  5 (3.1) a 26 (16.3) 12 (7.5) 64 (40) a 25 (15.6) 19 (11.9) 9 (5.6) a 0.005
No 7 (0.9) b 91 (11.9) 46 (6) 397 (52) b 134 (17.6) 72 (9.4) 16 (2.1) b
Treatment with metformin, n (%)
Yes 11 (1.7) 91 (14) 44 (6.8) 347 (53.3) a 110 (16.9) 43 (6.6) a 5 (0.8) a <0.001
No 1 (0.4) 26 (9.4) 14  (5.1) 117  (42.4) b 50  (18.1) 48 (17.4) b 20 (7.2) b
Sulfonylureas treatment, n (%)
Yes  3 (2) 22 (14.6) 4 (2.6) 82 (54.3) 24 (15.9) 12 (7.9) 4 (2.6) ns
No 9 (1.2) 95 (12.2) 54 (7) 382 (49.2) 136 (17.5) 79 (10.2) 21 (2.7)
Insulin treatment, n(%)
Yes  4 (1.7) 27 (11.5) 16 (6.8) 95 (40.6) a 42 (17.9) 36 (15.4) a 14 (6) a <0.001
No 8 (1.2) 90 (13) 42 (6.1) 369 (53.2) b 118 (17) 55 (7.9) b 11 (1.6) b
Thiazide treatment for HTN, n (%)
Yes 3  (0.8) 41 (11.4) 19 (5.3) 182 (50.7) 75 (20.9) 33 (9.2) 6 (1.7) ns
No 9 (1.6) 76 (13.4) 39 (6.9) 282 (49.6) 85 (15) 58 (10.2) 19 (3.3)
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– Table 3 (Continued)
mL/m/1.73 m2 G1 KD eGFR ≥ 90 G1 no KD eGFR ≥ 90 G2 KD eGFR 60–89 G2 no KD eGFR 60–89 G3A eGFR 45–59 G3B eGFR 30–44 G4-5 eGFR <30 p-Value*
ACEI/ARA I I treatment, n (%)
Yes  5 (0.8) a 72 (11.4) 45 (7.1) 297 (46.9) a 128 (20.2) 67 (10.6) 19 (3) <0.002
No 7 (2.4) b 45 (15.3) 13 (4.4) 167 (56.8) b 32 (10.9) 24 (8.2) 6 (2)
Statins treatment, n (%)
Yes 5  (0.8) 78 (12.9) 39 (6.5) 297 (49.3) 108 (17.9) 59 (9.8) 17 (2.8) ns
No 7 (2.2) 39 (12) 19 (5.9) 167 (51.5) 52 (16) 32 (9.9) 8 (2.5)
Albuminuria (mg/g), n (%) N = 608
<30  0 (0) a 74 (15.4) 0 (0) a 294 (61.1) a 73 (15.2) 32 (6.7) a 8 (1.7) <0.001
30–299 12 (11.1) b 0 (0) 52 (48.1) b 0 (0) b 23 (21.3) 16 (14.8) b 5 (4.6)
≥300 0 (0) b 0 (0) 6 (35.3) b 0 (0) b 3 (17.6) 7 (41.2) a 1 (5.9)
Dependency (Barthel), n (%)
Severe  0 (0) 3 (13) 3 (13) 9 (39.2) 3 (13) 4 (17.5) 1 (4.3) 0.028
Moderated 1 (2.4) 2 (4.9) 1 (2.4) 14 (34.1) a 16 (39) a 6 (14.6) 1 (2.4)
Mild 11 (1.3) 112 (12.9) 54 (6.2) 443 (51.2) b 141 (16.3) b 81 (9.4) 23 (2.7)
Comorbidity (Charlson), n (%)
Absence  4 (1.4) 51 (17.3) a 17 (5.8) 171  (58) a 37 (12.5) a 15 (5.1) a 0 (0) a <0.001
Low 4 (1.7) 33 (14.2) 13 (5.6) 141 (60.8) b 35 (15.1) 5 (2.2) b 1 (0.4) b
High 4 (1) 33  (8.4) b 28 (7.1) 148 (37.5) b 87 (22) b 71 (18) b 24 (6.1) b
SD: standard deviation; KD: kidney disease; eGFR: estimated glomerular filtration; HbA1c: glycosylated hemoglobin; HTN: hypertension; BMI: body mass index; M: mean; ns: not significant; R W/H:
waist height ratio.
The  categories G4–G5 have been grouped. In variables with more than two categories, (multiple comparisons) the letters a, b, or c indicate in which categories the differences are statistically significant.
Comparison of proportions by rows.
∗ For qualitative variables (n [%]): p-value chi-squared test (Bonferroni correction for multiple tests). For quantitative variables: parametric test (t-Student or ANOVA 1 factor) if they have a normal
distribution, nonparametric test (U-Mann Whitney, Kruskal Wallis test) otherwise.
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Table 4 – Factors associated with CKD in patients with DM2  ≥65 years (n = 929).
Univariate logistic regression model. Without
adjusting for the rest of the variables
Multivariate  logistic regression model.
Adjusted for the rest of the variables
OR (95% CI) p-Value OR (95% CI) p-Value
DM2 years 1.03 (1.01–1.05) 0.001 1.00 (0.98–1.03) 0.667
Age group (65–74 years old) 0.000 0.000
75–84 years 2.21 (1.63–3) 0.000 2.04 (1.46–2.84) 0.000
≥85 years 4.96 (3.27–7.52) 0.000 5.13 (3.15–8.35) 0.000
Group HBA1c (<7%) 0.093 0.084
7–8.5% 1.1 (0.82–1.48) 0.537 0.75 (0.53–1.08) 0.122
≥8.5% 1.61 (1.05–2.46) 0.029 1.31 (0.77–2.24) 0.318
BMI group ≥30 (yes) 1.14 (0.87–1.49) 0.346 1.12 (0.79–1.59) 0.514
Gender (woman vs. man) 1.07 (0.82–1.40) 0.609 1 (0.71–1.40) 0.995
Hypoglycemia group (yes) 1.75 (1.18–2.59) 0.005 1.45 (0.88–2.39) 0.146
Central obesity (yes) 1.15 (0.86–1.53) 0.352 0.98 (0.62–1.53) 0.923
R W/H Group >0.55 (yes) 1.24 (0.83–1.86) 0.300 1.34 (0.77–2.36) 0.303
Barthel Group (severe-total) 0.004 0.622
Moderate 1.70 (0.61–4.78) 0.311 1.77 (0.56–5.66) 0.332
Independent 0.61 (0.27–1.40) 0.242 1.40 (0.54–3.65) 0.489
Charlson group (absence) 0.000 0.000
Low comorbidity 1.91 (0.68–1.51) 0.947 0.94 (0.60–1.47) 0.778
High comorbidity 3.6 (2.58–5.00) 0.000 3.36 (2.20–5.12) 0.000
Macrovascular Dis (yes) 1.69 (1.26–2.26) 0.000 0.88 (0.59–1.32) 0.547
Microvascular Dis (yes) 1.38 (0.96–1.95) 0.068 0.75 (0.48–1.15) 0.187
Treatments
Antiaggregants 1.24 (0.94–1.63) 0.121 1.08 (0.75–1.55) 0.676
Anticoagulants 1.97 (1.35–2.88) 0.000 1.51 (0.96–2.37) 0.078
Anti-HTN 2.95 (1.89–4.59) 0.000 2.43 (1.48–4.02) 0.000
OAD (hypoglycemic agents) 0.60  (0.42–0.84) 0.003 0.80 (0.53–1.21) 0.298
Insulin 1.80 (1.33–2.43) 0.000 1.13 (0.72–1.75) 0.598
OAD: oral antidiabetics; DM2: diabetes mellitus type 2; Dis: disease; KD: kidney disease; HbA1c: glycosylated hemoglobin; HTN: arterial hypertension; CI: confidence interval; BMI: body mass index;
OR: odds ratio; R W/H: waist circumference/height.
1 8;3  8
d
w
t
s
i
h
g
o
a
(
s
y
g
3
s
d
a
w
3
1
c
t
i
y
p
p
s
N
l
i
D
i
w
s
m
c
e
s
a
a
t
p
u
w
p
i
o
a
i
e
o
t
a
w
u
b
f
l
un e f r o l o g i a. 2 0 
eterminations were  made to confirm the results. Previous
ork  done in the province of Teruel25 in a diabetic popula-
ion  over 18 years of age, mean age 67.9 years and with a
ingle  analytical determination, showed a prevalence of CKD
n  34.6%, RI in 25.2% and albuminuria in 16.1% (moderately
igh 14.3%, severely increased 1.8%). Also in our country, Vina-
re  et al.23 reported in diabetics over 30 years of age, mean age
f  68.2 years and average duration of their DM2 of 6.5 years,
 prevalence of RI in 20% and albuminuria in 16.7% of patient
moderately high in 14.9%, severely elevated in 1.8%). In the
tudy  by Coll et al.4 in patients with DM2  with a mean age of 68
ears,  mean duration of their diabetes 7 years and with a sin-
le  determination of albuminuria, the prevalence of CKD was
4.1%,  RI in 22.9% and albuminuria in 19.5%, values that are
imilar  to the obtained in our study. In Finland, in a study con-
ucted  in PC centers9 in diabetics over 29 years of age, mean
ge  67 years, average duration of their diabetes 9.2 years and
ith  a single determination of ACR, the prevalence of CKD was
4.7%,  RI in 16.2% and albuminuria in 24.3% (moderately high
7.1%,  severely elevated 7.2%), it should be stressed the per-
ent  of severely elevated albuminuria, which double or triple
hose  observed in Spanish studies. Another study conducted
n  PC in Switzerland,10 in patients with an average age of 66.5
ears  and an average duration of DM2  of 9.3 years, showed a
revalence of CKD of 45.4% and RI of 22.4%; only 30% of the
atients  contributed one determination of albuminuria. The
tudy  by Wu et al.,8 using data from the US National Health and
utrition  Examination Surveys 2007–2012, with a single ana-
ytical  determination, reported a prevalence of CKD of 38.3%
n  diabetics over 18 years of age with an average duration of
M2  of 10 years; the prevalence of RI was  19.8%. Consider-
ng  only patients older than 65 years, the prevalence of CKD
as  58.7% and RI 40.8%, which are almost double than in our
tudy.  The different prevalences reported by separate studies,
ay  be due to methodological differences, a single analyti-
al  determination or several to confirm the results, or to the
thnic  and demographic characteristics of the population.
Early  detection of CKD has important clinical implications
ince both albuminuria and decreased glomerular filtration
re  independently associated with cardiovascular morbidity
nd  mortality as well as total mortality26; thus, it may  condi-
ion  the therapeutic options of DM2  and other comorbidities
resent in this type of patients. In our study, 82.3% of patients
sed  some type of oral antidiabetics and 25.2% were treated
ith  insulin. Metformin is the OAD most used, in 70.2% of
atients  and only 0.8% used Metformin outside the current
ndication of the European Medicines Agency27 (stages G4–G5
f  ERC) and the Spanish Consensus Documents on detection17
nd treatment of DM2  in the patient with CKD,28 even though
n  the technical data sheet of metformin it is contraindicated if
GFR < 60 mL/m/1.73 m2. Sulfonylurea (SU) was  used by 16.3%
f  patients (2.6% in stages G4–G5 out of indication).17,28 In
he  study by Ruiz Tamayo et al.,29 88.4% used metformin,
nd in 36.4% of the cases it was  out of formal indication; SU
as  used by 31.1% of the patients, in 66% of the cases the
sed  was  out of indication. This important discrepancy may
e  due to the involvement of the medical researchers in the
ollow-up  of their diabetic patients (in our study) or to the
ack  of registration of the prescription. Muller et al.24 reported
se  of metformin use in 45.2% of patients (49.3% out of(4):395–407  405
indication), 32.2% used SU (26.7% out of indication) and 34.5%
were  on insulin, with a progressive increase in its use accord-
ing  to the deterioration of renal function. In another French
study,30 86% of patients used metformin (33% out of indica-
tion),  32% were on SU (20% off-label cases) and 19% in patients
on  insulin (61% in more  severe stages of CKD).). In the Swiss
study,10 74% used metformin (43.8% off-label), 20.5% used SU
(9.4%  off-label) and 28.9% used insulin (50% in CKD Stages
G4,G5).  In the study by Wu  et al.,8 55.6% of diabetics used met-
formin  (6.5% in CKD stages G4–G5), a 35.4% used SU (in more
than  50% of the case out of indication) and 18.9% used insulin
(38%  in stages G4–G5 of ER). This study also reports the use
of  inhibitors of the renin–angiotensin–aldosterone system for
the  treatment of hypertension in 62% of patients (in our study
it  reach almost 70%) and the use of thiazide diuretics in 23.7%
of  diabetic hypertensive patients (33.4% in stage G4 of CKD),
while  in our study, 38.7% of hypertensive diabetics used this
group  of drugs, only 1.7% with eGFR < 30 mL/m/1.73 m2 situ-
ation  in which its use is not recommended due to lack of a
significant  effect. In short, although the various studies tend to
reflect, in their prescription pattern, the recommendations of
the  guidelines for the treatment of individuals with CKD,31 the
number  of patients using some OADs outside of the indication
is  strikingly high.
In  our study, 7% of the patients presented a moderate-total
degree of dependence and 42.8% had a high comorbidity, both
entities  being related to the deterioration of renal function. A
56.1% of patients with moderate dependence and 34.8% with
severe  dependence have CKD, 17.7% of patients with aver-
age  comorbidity and 46.1% of those with high comorbidity
have RI. It should be noted that in the study REAnal Disease
Morbidity in diabetic and non-diabetic patients (MERENA),32,33
launched by the Spanish Study Group of Diabetic Nephropa-
thy,  the baseline study data corresponding to 1129 patients
with  CKD stages 3 and 4, show that the cohort of diabetic
patients (40.8% of the total, 91.7% DM2) has greater cardio-
vascular morbidity than the non-diabetic population. In the
study  by Kim et al.,34 conducted in Korea, patients had an
average  Charlson Index of 3.3 (2.7 in our study) and 60.8% of
the  patients had a high comorbidity (Charlson ≥3) that was
associated  with twice the risk of hypoglycemic episodes.
The  multivariate analysis supports previous research that
identifies  advanced age, treated HTN and the presence of high
comorbidity  as potential factors of CKD in the diabetic popu-
lation;  contrary to other reports, we  did not find an association
with  the duration of DM, HbA1c and gender.4,8,12
The strengths of our work are: first, it includes characteris-
tics  of a group of patients underrepresented in clinical trials.
Second,  it measures the degree of dependence and comorbid-
ity  of the participants.
The  study has several limitations: albuminuria was  only
provided  by 65.5% of the patients and only one analytical
determination was  collected, which is usual in epidemio-
logical studies but does not allow to distinguish between a
transient  and persistent alteration. Therefore, the estimates
of  CKD reported in this work may  have been higher than
if  the eGFR and ACR measures were repeated to meet the
KDIGO16 criteria and the Spanish consensus document,17 to
demonstrate persistence of alterations for 3 or more  months
for  diagnosis of chronic kidney disease. The availability of
 0 1 8
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CAC values in all participants could reduce the possible over-
estimation,  in fact if only patients who contributed with
albuminuria were  considered, the prevalence of CKD was
39.5%.  The race was  not taken into account in the calcula-
tion  of the eGFR, a situation that is not very relevant given the
homogeneous  characteristics of the population studied.
Conclusions
Chronic Kidney Disease is common in the elderly diabetic
population and it is associated with a high frequency of con-
comitant  chronic diseases and a greater degree of dependence.
The  use of metformin and sulfonylureas in advanced stages
of  Renal insufficiency is scarce but should be adjusted or elim-
inated  in each case, since the use may  by inadequate. Insist
on  the need to determine the ACR in urine as a necessary tool
for  the detection of CKD, since these patients with diabetes
and  CKD require careful attention and monitoring. They have
a  high risk of cardiovascular disease and suffer side effects
from  medications. However, it is likely that these problems are
usually underestimated in clinical practice, so greater empha-
sis  should be placed on alerting professionals to act in these
situations.
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